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Summary: VLDL cholesterol concentrations were determined in 1641 male and 608 female and VLDL
apolipoprotein B concentrations in 505 male and 211 female Company employees in Westphalia aged 17 — 70
i years.
VLDL cholesterol and VLDL apolipoprotein B values were found to be distributed with positive skew in
both sexes but were higher in men than in women (median in men: VLDL cholesterol 0.30 mmol/1, VLDL
apolipoprotein B 0.066 g/l, median in women: VLDL cholesterol 0.18 mmol/1, VLDL apolipoprotein B
0.047 g/l).
In males VLDL cholesterol and VLDL apolipoprotein B were closely correlated to each other (r = 0.757)
äs well äs to triacylglycerols (VLDL cholesterol: r = 0.673, VLDL apolipoprotein B: r = 0.707) and HOL
cholesterol (VLDL cholesterol: r = 0.509, VLDL apolipoprotein B: r = —0.419). In females these observed
correlatioiis were weaker.
The VLDL cholesterol/VLDL apolipoprotein B ratip was also higher in men (median 4.28 mmol/g) than in
women (median 3.15 mmol/g). The ratio correlated to triacylglycerols (men: r = 0.591, women: r = 0.321).
The results suggest thät the composition of VLDL may be related to triacylglycerols in serum.
Introduction
 increased levds of VLDL and triacylglycerols
Apolipoprotein B represents the functional entity of are obviously associated with premature athero-
several lipoproteins in plasma, especially of very low sclerosis (5). The reason for the potential role of
density lipoproteins (VLDL) and low density lipopro- VLDL in atherogenesis may be associated with the
teins (LDL). Normally, more than 90% of total apoli- observation thät in several hypertriacylglycerolaemic
poprotein B in plasma is transported in LDL, patients an altered composition of VLDL can be
whereas approximately 4—5% of total apolipopro- found which is characterised by an enhancement of
tein B is found in VLDL (1). While enhanced LDL the cholesterol component of these particles (6). Fur-
have been well established äs a primary risk factor thermore, according to studies of Franceschini (7)
for coronary heart disease (25 3) increased VLDL in increased concentrations of apolipoprotein B in
plasma generally may not be a primary risk factor, VLDL are associated with peripheral vascular dis-
but rather a reflection of the existence of other risk ease. Therefore, the VLDL composition may be of
factors (4). On the other hand, in several clinical special clinical and epidemiological significance,
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However, the determination of VLDL components
has hitherto been a time consuming method, involv-
ing the Separation of VLDL by ultracentrifugation.
Recently a commercial test was developed for the
selective precipitation of LDL with polyvinylsulphate
(8,9). Using this procedure VLDL cholesterol äs well
äs VLDL apolipoprotein B (10) can be easily analysed
in the superanatant obtained following LDL precipi-
tation.
The present paper reports preliminary results of our
epidemiological study in Westphalia (11) regarding
the relationship of VLDL apolipoprotein B and
VLDL cholesterol to several lipid parameters.
Materials and Methods
Sample material
As test material we used fresh serum from the test series
Prospective Epidemiological Study on Company Employees in
Westphalia (11).
Methods
Analysis oflipids
Analyses of cholesterol and triacylglycerols were performed
with the SMAC Analyser (Technicon GmbH, Bad Vilbel, FRG)
äs described elsewhere (11).
Analysis of HDL cholesterol
HDL cholesterol was enzymatically analysed using the CHOD-
PAP method (Boehringer Mannheim Test Combination No.
187313) äs described elsewhere (12).
Analysis of VLDL components
VLDL components were determined in the supernatant ob-
tained following selective precipitation of LDL with polyvinyl-
sulphate äs described elsewhere in detail (8, 9). VLDL choleste-
rol was determined äs the difference between cholesterol in the
supernatant (which was enzymatically analysed äs described
for HDL cholesterol) and HDL cholesterol. VLDL apolipopro-
tein B was determined äs described elsewhere in detail (10).
Statistics
Since both parameters were distributed with positive skew, non-
parametric statistic methods were used.f In correiation arialysis
Spearman's rank correiation coefficients are given.
Differences in the distribution between subgroups were tested
by Mann-Whitney^ U-test (two groups) or by the rriethod of
Nemenyi (multiple comparisons). The level of significahce was
set at 0.05.
Results
Distribution of VLDL cholesterol and
VLDL apolipoprotein B values in no-rmal
individuals
In both sexes VLDL cholesterol and VLDL apolipo-
protein B values were distributed with positive skew
(flg. l and fig. 2). Men exhibited obviously higher
levels of VLDL cholesterol (median: 0.30 mmol/1, 5th
percentile 0.06 mmol/1, 95th percentile 1.19 mmol/1)
äs well äs VLDL apolipoprotein B (median: 0.066 g/l,
5th percentile 0.041 g/l, 95th percentile 0.173 g/l) than
women (VLDL cholesterol: median 0.18 mmol/1, 5th
percentile 0.033 mmol/1, 95th percentile 0.57 mmol/1,
VLDL apolipoprotein B: median 0.047 g/l> 5th per-
centile 0.030 g/l, 95th percentile 0.075 g/l) (p < 0.001
each).
In the group in which VLDL cholesterol was deter-
mined, 28% of the women took oral contraceptives
at the time of the study; in the group for VLDL
apolipoprotein B determination, this figure was
22.8%. Women who took the "pill" showed margi-
nally but not significantly raised levels of VLDL
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Tab. l. Correlation coefficients between VLDL cholesterol, VLDL apolipoprotein B and lipid parameters.
VLDL cholesterol
Cholesterol
Triacylglycerols
HDL cholesterol
Men
(n = 1641)
0.089***
0.673***
-0.509***
Women
(n = 608)
-0.015
0.365***
-0.344***
VLDL apolipoprotein B
Men
(n = 505)
0.176***
0.707***
-0.419***
Women
(n = 211)
-0.142*
0.250***
-0.245***
* p <0.05 *** p < 0.001
cholesterol (median: 0.192 mmol/1, 0.175 mmol/1 re-
spectively), whereas the difference in VLDL apolipo-
protein B values was more pronounced (median:
0.057 g/l and 0.046 g/l, p <0.01). This difference was
age-independent. There were no statistically relevant
differences for the two parameters for women who
had never or had in the past been on the pill.
Correlation of VLDL cholesterol and VLDL
apolipoprotein B with lipid parameters
In men there was a strong positive correlation be-
tween VLDL cholesterol and VLDL apolipopro-
tein B values (r = 0.757, n = 505). In women the
positive correlation between these parameters was
weaker (r = 0.362, n = 211).
In men both VLDL components were significantly
correlated with all the lipid parameters that were
considered (tab. 1), but the correlations with choleste-
rol were weaker than those with triacylglycerols and
HDL cholesterol. In women the correlations between
both VLDL components and lipid parameters were
much weaker than in men (tab. 1). In both sexes and
both VLDL components the correlation coefficients
of triacylglycerols were the highest. Obviously, the
VLDL cholesterol values increased more than VLDL
apolipoprotein B values with increasing triacylglycer-
ols.
VLDL cholesterol/VLDL apolipoprotein B
ratio
To test whether the composition of VLDL ,may be
related to lipid parameters, the VLDL cholesterol/
VLDL apolipoprotein B ratio was computed. Like
the single parameters the ratio was higher in males
(median 4.28 mmol/g, 5th percentile 0.94 mmol/g,
95th percentile 8.94 mmol/g) than in females (median
3.15 mmol/g, 5th percentile 0.77 mmol/g, 95th percen-
tile 8.50 mmol/g) (fig. 3, p < 0.001). The correlation
analysis also showed comparable results to those of
the single parameters (tab. 2).
Tab. 2. Correlation coefficients between VLDL cholesterol/
VLDL apolipoprotein B ratio and lipid parameters.
Cholesterol
Triacylglycerols
HDL cholesterol
Men
(n = 505)
0.069
0.591***
-0.483***
Women
(n = 211)
0.036
0.321***
-0.293***
*** p < 0.001
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The highest correlation coefficients were found be-
tween triacylglycerols and the ratio of VLDL compo-
nents in males (r = 0.591) äs well äs in females (r =
0.321). Furthermore, VLDL cholesterol äs well äs
VLDL apolipoprotein B values in the three
subgroups of men with normal (<1.71 mmol/1) and
high (>2.28 mmol/1) triacylglycerols differed from
each other (tab. 3, p <0.01). Since the differences
in VLDL cholesterol were greater than in VLDL
apolipoprotein B the ratio showed significantly dif-
ferent values (p <0.05, tab. 3). The number of hyper-
lipidaemic women was too small to test this observa-
tion in females.
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Tab. 3. Medians of VLDL cholesterol, VLDL apolipoprotein B
and VLDL cholesterol/VLDL apolipoprotein B ratio in
subgroups with different triacylglycerol concentrations
(men only).
Triacylglycerol
concentration
<1.71 mmol/1
1.71- 2.28 mmol/1
>2.28 mmol/1
VLDL
cholesterol
(mmol/1)
0.25
(n = 1044)
0.40
(n = 261)
0.78
(n = 336)
VLDL
apolipo-
protein B
(g/D
0.058
(n = 316)
0.080
(n = 82)
1.18
(n = 107)
VLDL
cholesterol/
VLDL apo-
lipoprotein B
ratio
(mmol/g)
3.33
(n = 316)
4.55
(n = 82)
7.69
(n = 107)
Discussion
In contrast to the determination of apolipoprotein B
in total plasma, the determination of apolipopro-
tein B äs a component of lipoproteins, especially of
VLDL, is not yet a routine method, due to the time
consuming Separation of lipoproteins by ultracentri-
fugation. Using the recently developed selective preci-
pitation procedure for LDL (8), VLDL apolipopro-
tein B can be determined correctly and easily in the
supernatant (10). Our VLDL apolipoprotein B values
äs well äs VLDL cholesterol values for males agree
well with the results recently described by Vega &
Grundy (15). To our knowledge, VLDL apolipopro-
tein B has not yet been extensively investigated in
females. As described for VLDL cholesterol (16) the
apolipoprotein B values obtained in females are ob-
viously lower than in males.
The present study showed strikingly close correla-
tions between triacylglycerols and VLDL apolipopro-
tein B äs well äs between triacylglycerols and VLDL
cholesterol. However, in both sexes the correlation
between triacylglycerols and VLDL apolipoprotein B
was weaker than the corresponding correlation be-
tween triacylglycerols and VLDL cholesterol. Hyper-
triacylglycerolaemia may therefore be reflected r ather
by increased VLDL cholesterol than by increased
VLDL apolipoprotein B in plasma. Sirice in hypertri-
acylglycerolaemic individuals (>2.28 mmol/1) VLDL
cholesterol was more enhanced than VLDL apolipo-
protein B in hypertriacylglycerolaemic individuals the
ratio VLDL cholesterol/VLDL apolipoprotein B is
clearly higher than in normotriacylglycerolaemic süb-
jects. Our results agree well with recent fmdings of
Eisenberg et al. (6, 17). These authors have shown
that hypertriacylglycerolaemia resulted in an altered
composition of VLDL particles which are enriched
in cholesterol at the cöst of apolipoproteins. The
reason for this observation has been suggested to be
a reflection of an enhanced activity of lipid transfer
reactions between lipoproteins in hypertriacylglycer-
olaemic plasma (6, 17, 18). According to this view,
the presence of a high concentration of triacylglyc-
erol-rich lipoproteins in plasma induces accelerated
transfer of cholesteryl esters from LDL and HOL to
VLDL and triacylglycerols in the opposite direction
(19).
This transfer may result in VLDL particles relatively
enriched in cholesteryl esters (and LDL and HOL
particles relatively enriehed in triacylglycerols). Since
the triacylglycerol level in plasma in females is lower
than in males (16), and since prevalence of hypertri-
acylglycerolaemia in females is relatively low (11), it
can be suggested that in females VLDL are relatively
poorer in cholesterol and relatively richer in apolipo-
proteins than in males. This supposition was sup-
ported by our observation that in females the ratio
VLDL cholesterol/VLDL apolipoprotein B is lower
than in males. Another indicator for differeiices in
VLDL composition between males and females is our
observation that in females the correlation between
VLDL cholesterol and VLDL apolipoprotein B was
relatively weak, while in males the corresponding
correlation was relatively close.
The significance of alterations in VLDL composition
in relation to the risk of atherosclerosis is an open
question and deserves further investigation.
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